We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Ocular Surface Squamous Neoplasia From Blue Skies to Blue Dyes—We Still Need Our Ophthalmic Pathologists

Carol L. Shields, MD1; Jerry A. Shields, MD1
[+] Author Affiliations
1The Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. 2015;133(11):1321-1322. doi:10.1001/jamaophthalmol.2015.3359.
Text Size: A A A
Published online


Without question, ocular surface squamous neoplasia (OSSN) is a solar-related condition, particularly endemic in immunosuppressed patients.13 This viral-related tumor of the conjunctival surface epithelium tends to occur in sun-exposed regions of the eye, most often at the nasal or temporal limbus. This tumor can have protean clinical manifestations as a gelatinous, translucent, foamy, leukoplakic, vascular, or pigmented mass.3,4 Risks for tumor growth onto the cornea, into the fornix, and rarely into the orbit, producing ultimate risk for metastatic disease, are understood. Treatment paradigms have shifted over the past 20 years from exclusive surgical removal using the “no-touch” technique with superficial corneal epitheliectomy and conjunctival cryotherapy3 to surgical or nonsurgical strategies using topical antitumor medications such as mitomycin C, 5-fluorouracil, interferon alpha-2b (also available as injection), cidofovir, photodynamic therapy, and even more curious methods, including topical aloe vera.3,57 The goal of therapy is complete eradication of this low-grade malignancy to prevent recurrence, orbital invasion, metastatic disease, and death.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections